Skip to content
Inciteful Med

Diagnosis & Testing: Finding the Hidden Deficiency

Last updated:

Diagnosing Factor XIII deficiency requires a specific Quantitative Factor XIII Activity Assay because standard clotting tests (PT, aPTT) usually appear normal. Older clot solubility tests are unreliable and often miss mild cases. Subtype testing (A vs. B) is essential for selecting the right treatment.

Key Takeaways

  • • Standard coagulation tests (PT, aPTT) are almost always normal in Factor XIII deficiency, leading to missed diagnoses.
  • • The older Clot Solubility Test is unreliable and often misses mild or moderate cases of deficiency.
  • • The Quantitative Factor XIII Activity Assay is the gold standard for accurate diagnosis and measuring severity.
  • • Subtype testing (A vs. B) is crucial because it determines which specific treatments will work for you.

Diagnosing Factor XIII (FXIII) deficiency is often described as a “medical detective story.” Because the condition is so rare and the most common blood tests appear perfectly normal, it is easy for this deficiency to remain hidden for years [1][2].

The Diagnostic Trap

When you visit a doctor for bleeding concerns, they typically start with a standard “coagulation panel.” This panel includes tests like PT, aPTT, and Platelet Counts.

In Factor XIII deficiency, these standard tests are almost always normal [3][4]. This is the primary diagnostic trap. A doctor who is not familiar with rare bleeding disorders may see these “perfect” results and incorrectly conclude that there is no bleeding problem. If you have symptoms like delayed bleeding or umbilical stump bleeding, you must look beyond these basic screens [5][6].

The Clot Solubility Test: An Older Screen

Historically, the most common way to look for FXIII deficiency was the Clot Solubility Test (sometimes called the Urea or Acetic Acid test). In this test, a blood clot is placed in a chemical solution. If the clot dissolves quickly, it suggests a lack of Factor XIII [7][8].

  • The Problem: This is a “pass/fail” test and is not very sensitive. It effectively finds severe deficiency (levels below 1%) but frequently misses mild or moderate cases (levels between 2% and 30%) [9][10].
  • The Verdict: International guidelines no longer recommend this as the only screening tool because it misses too many patients [11][12].

The Gold Standard: Quantitative Functional Assays

The modern “gold standard” for diagnosis is the Quantitative Factor XIII Activity Assay (often using an “ammonia release” or “photometric” method) [5][13].

Unlike the pass/fail test, this assay provides a specific number (a percentage). For example, it might show that a patient has exactly 4% activity. This precision is vital for:

  1. Confirming even mild cases that the solubility test missed [14].
  2. Determining the severity of the condition [15].
  3. Monitoring how well treatment is working [16].

Subtype Testing: A vs. B

Once a deficiency is found, the next step is Antigen Testing to determine if the problem is with Subunit A or Subunit B [17][18].

  • Type A Deficiency: The most common and usually the most severe form [15].
  • Type B Deficiency: Often milder [19].
    Knowing the subtype is essential because some modern treatments, such as recombinant Factor XIII-A, are only effective for patients with Type A deficiency [20][21].

Checklist for Your Doctor

If you suspect FXIII deficiency, you can help your medical team by requesting these specific steps:

  1. Request a Quantitative Assay: Explicitly ask for a “Quantitative Factor XIII Activity Assay,” not just a “Clot Solubility Screen” [11].
  2. Order Subunit Testing: If activity is low, request “FXIII-A and FXIII-B Antigen” tests to find the subtype [17].
  3. Consider Genetic Testing: Genetic testing can confirm the exact mutation in the F13A1 or F13B genes, which is helpful for family planning [22][6].
  4. Rule out Inhibitors: Especially in adults who develop symptoms later in life, doctors should check for inhibitors (antibodies) that might be attacking the Factor XIII [16][23].

Frequently Asked Questions

Why are my clotting tests normal if I have Factor XIII deficiency?
Standard coagulation tests like PT and aPTT measure how fast a clot forms, but they do not measure how strong or stable the clot is. Since Factor XIII is responsible for stabilizing the clot after it forms, a deficiency does not show up on these standard screening tests.
Is the clot solubility test reliable for diagnosis?
No, the clot solubility (urea) test is an older "pass/fail" method that is not very sensitive. It frequently misses mild or moderate cases of deficiency. International guidelines now recommend using a quantitative activity assay instead.
What is the best test to diagnose Factor XIII deficiency?
The gold standard is the Quantitative Factor XIII Activity Assay. Unlike older screening methods, this test provides a specific percentage of factor activity, allowing doctors to detect even mild deficiencies and measure severity accurately.
Why do I need to test for Subunit A vs Subunit B?
Subtype testing determines whether the deficiency is in Subunit A or Subunit B. This is critical because certain modern treatments, such as recombinant Factor XIII-A, are only effective for patients with a Subunit A deficiency.
What is an inhibitor screen?
If you develop Factor XIII deficiency later in life (acquired), doctors need to check for inhibitors. These are antibodies that your immune system produces which attack and neutralize your own Factor XIII protein.

Questions for Your Doctor

  • • Can we confirm that a quantitative activity assay was used, and not just a pass/fail solubility test?
  • • What is my (or my child's) exact Factor XIII activity percentage?
  • • Did the antigen testing show a deficiency in Subunit A or Subunit B?
  • • Is there any evidence of an inhibitor (antibody) that would suggest this is an acquired deficiency rather than a congenital one?
  • • Would genetic testing be helpful for our family to identify the specific mutation?

Questions for You

  • • Was the initial diagnosis made because of a specific bleeding event, or through family screening?
  • • If a 'clot solubility test' was done and came back normal, but I still have symptoms, should I request the quantitative test?
  • • Have I shared my full family history of 'unexplained' bleeding or miscarriages with the hematologist?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Acquired Factor XIII Deficiency in a 19-year-Old Male Following Ballistic Injury.

    Rodgers SC, Carter KT, Kutcher ME, Iwuchukwu CO

    The American surgeon 2022; (88(9)):2225-2226 doi:10.1177/00031348221091970.

    PMID: 35476509
  2. 2

    Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.

    Cohen EL, Millikan SE, Morocco PC, de Jong JLO

    Case reports in pediatrics 2021; (2021()):5550199 doi:10.1155/2021/5550199.

    PMID: 34007504
  3. 3

    Choroid Plexus Papilloma and Factor XIII Deficiency: Case Report.

    Aydin Ozturk P, Sanri O, Yilmaz A, et al.

    Pediatric neurosurgery 2018; (53(6)):413-415 doi:10.1159/000492334.

    PMID: 30176663
  4. 4

    A case of anti-NPX-2 antibody-positive dermatomyositis resulting in massive haemothorax with acquired factor XIII deficiency.

    Matsuda T, Haga T, Sakaguchi T, et al.

    Modern rheumatology case reports 2023; (8(1)):91-94 doi:10.1093/mrcr/rxad049.

    PMID: 37606624
  5. 5

    State of the art in factor XIII laboratory assessment.

    Durda MA, Wolberg AS, Kerlin BA

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2018; (57(6)):700-704 doi:10.1016/j.transci.2018.07.006.

    PMID: 30087086
  6. 6

    Congenital factor XIII deficiency caused by F13A1 gene mutations presenting with intracranial hemorrhage: a case report.

    Wang H, Yang R, Li J

    Frontiers in pediatrics 2025; (13()):1732065 doi:10.3389/fped.2025.1732065.

    PMID: 41488895
  7. 7

    Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran.

    Dorgalaleh A, Alavi SE, Tabibian S, et al.

    Hematology (Amsterdam, Netherlands) 2017; (22(4)):224-230 doi:10.1080/10245332.2016.1263007.

    PMID: 27894217
  8. 8

    First cases of severe congenital factor XIII deficiency in Southwestern Afghanistan in the vicinity of southeast of Iran.

    Hosseini S, Dorgalaleh A, Bamedi T, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2015; (26(8)):908-11 doi:10.1097/MBC.0000000000000358.

    PMID: 26226252
  9. 9

    Subgaleal Hematoma in a Female With Normal Coagulation Tests.

    Ataei-Azimi S, Bos MHA, Rahimi H, Mansouritorghabeh H

    Case reports in hematology 2025; (2025()):5481806 doi:10.1155/crh/5481806.

    PMID: 40919234
  10. 10

    Molecular diagnosis of factor XIII deficiency, data from comprehensive coagulation laboratory in Iran.

    Gheidishahran M, Dorgalaleh A, Tabibian S, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2018; (29(1)):87-91 doi:10.1097/MBC.0000000000000679.

    PMID: 29095761
  11. 11

    Factor XIII deficiency diagnosis: Challenges and tools.

    Karimi M, Peyvandi F, Naderi M, Shapiro A

    International journal of laboratory hematology 2018; (40(1)):3-11 doi:10.1111/ijlh.12756.

    PMID: 29027765
  12. 12

    Diagnosis of factor XIII deficiency.

    Dorgalaleh A, Tabibian S, Hosseini MS, et al.

    Hematology (Amsterdam, Netherlands) 2016; (21(7)):430-9 doi:10.1080/10245332.2015.1101975.

    PMID: 27077776
  13. 13

    Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity.

    Leitner M, Büchold C, Pasternack R, et al.

    International journal of molecular sciences 2021; (22(3)) doi:10.3390/ijms22031002.

    PMID: 33498248
  14. 14

    Acquired factor XIII deficiency is associated with mortality and is not linked to hypocalcemia.

    Duque P, Esteban ML, Piñeiro P, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2026; (37(1)):28-37 doi:10.1097/MBC.0000000000001400.

    PMID: 41311329
  15. 15

    Factor XIII deficiency in south of Tunisia.

    Maaloul I, Medhaffer M, Louhichi N, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2017; (28(6)):485-489 doi:10.1097/MBC.0000000000000649.

    PMID: 28704210
  16. 16

    [A Case of Autoimmune Acquired Factor XIII Deficiency Diagnosed from Recurrent Postoperative Bleeding].

    Takashima Y, Kawanishi H, Kotani S, et al.

    Hinyokika kiyo. Acta urologica Japonica 2023; (69(6)):169-173 doi:10.14989/ActaUrolJap_69_6_169.

    PMID: 37460281
  17. 17

    An international collaborative study to assign value for Total Factor XIII-B Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): Communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen.

    Raut S, Katona É, Riches-Duit A, et al.

    Journal of thrombosis and haemostasis : JTH 2022; (20(2)):525-531 doi:10.1111/jth.15596.

    PMID: 34784091
  18. 18

    A Targeted LC-MS/MS-Based Quantitative Assay for Detecting Plasma Factor XIII A/B Subunit Deficiency.

    Kim J, Venkataraman S, Chavan SN, et al.

    The Journal of molecular diagnostics : JMD 2026; (28(1)):64-74 doi:10.1016/j.jmoldx.2025.09.010.

    PMID: 41176274
  19. 19

    Factor XIII Deficiency: Laboratory, Molecular, and Clinical Aspects.

    Dorgalaleh A, Jozdani S, Zadeh MK

    Seminars in thrombosis and hemostasis 2025; (51(2)):155-169 doi:10.1055/s-0044-1796673.

    PMID: 39613144
  20. 20

    Treatment with Recombinant Factor XIII (Tretten) in a Pregnant Woman with Factor XIII Deficiency.

    Abdel-Samad N

    The American journal of case reports 2017; (18()):436-439 doi:10.12659/ajcr.901502.

    PMID: 28432284
  21. 21

    Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration.

    Byrnes JR, Lee T, Sharaby S, et al.

    Blood 2024; (143(5)):444-455 doi:10.1182/blood.2023022042.

    PMID: 37883802
  22. 22

    Premarital Screening Program for Congenital Factor XIII Deficiency in Iran.

    Daneshi M, Dorgalaleh A, Tabibian S, et al.

    Clinical laboratory 2020; (66(8)) doi:10.7754/Clin.Lab.2020.191133.

    PMID: 32776739
  23. 23

    Retroperitoneal fibrosis in presence of autoimmune coagulation factor XIII deficiency result in recurrent critical post-operative hemorrhage: a case report and molecular research with new insights.

    Matsushita T, Tachibana M, Nakagawa H, et al.

    Frontiers in immunology 2025; (16()):1591847 doi:10.3389/fimmu.2025.1591847.

    PMID: 40709186

This guide explains diagnostic testing for Factor XIII deficiency for educational purposes. Always consult a hematologist for proper diagnosis and interpretation of your specific test results.

Stay up to date

Get notified when new research about Factor XIII Deficiency is published.

No spam. Unsubscribe anytime.